News Snapshot:
In the largest study yet to evaluate a common, low-cost antidepressant as a treatment for COVID-19, researchers from Washington University School of Medicine in St. Louis and from Canada and Brazil have found that the drug fluvoxamine prevents some of the most serious complications of COVID-19, sharply reducing the risk of hospitalization and death. The trial, conducted in Brazil, confirms results from the first trial of fluvoxamine for COVID-19, which was launched in early 2020 at Washington University School of Medicine in St. Louis. The Brazilian study followed about 1,500 patients newly diagnosed with COVID-19. Of them, 741 people received...
